PNC Financial Services Group Inc. Cuts Stock Holdings in Abbott Laboratories $ABT

PNC Financial Services Group Inc. reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 0.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 4,580,444 shares of the healthcare product maker’s stock after selling 11,966 shares during the period. PNC Financial Services Group Inc.’s holdings in Abbott Laboratories were worth $613,505,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Uhlmann Price Securities LLC lifted its stake in shares of Abbott Laboratories by 8.7% during the third quarter. Uhlmann Price Securities LLC now owns 3,800 shares of the healthcare product maker’s stock valued at $509,000 after buying an additional 303 shares during the period. GF Fund Management CO. LTD. raised its position in shares of Abbott Laboratories by 30.6% in the 3rd quarter. GF Fund Management CO. LTD. now owns 47,943 shares of the healthcare product maker’s stock worth $6,421,000 after buying an additional 11,241 shares during the period. Cidel Asset Management Inc. boosted its holdings in Abbott Laboratories by 2.0% in the third quarter. Cidel Asset Management Inc. now owns 335,841 shares of the healthcare product maker’s stock valued at $44,983,000 after acquiring an additional 6,660 shares during the last quarter. MidWestOne Financial Group Inc. increased its stake in Abbott Laboratories by 0.3% during the third quarter. MidWestOne Financial Group Inc. now owns 39,597 shares of the healthcare product maker’s stock worth $5,304,000 after acquiring an additional 131 shares during the last quarter. Finally, DDD Partners LLC boosted its holdings in Abbott Laboratories by 3.0% in the 3rd quarter. DDD Partners LLC now owns 129,596 shares of the healthcare product maker’s stock worth $17,358,000 after acquiring an additional 3,723 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $112.63 on Friday. The firm has a fifty day moving average price of $119.48 and a two-hundred day moving average price of $126.40. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The company has a market cap of $195.84 billion, a PE ratio of 30.28, a price-to-earnings-growth ratio of 1.79 and a beta of 0.75. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, February 13th. Investors of record on Thursday, January 15th were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s payout ratio is 67.74%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ABT shares. The Goldman Sachs Group reduced their price target on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Leerink Partners decreased their target price on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Raymond James Financial dropped their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Finally, Oppenheimer dropped their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $137.05.

Insider Transactions at Abbott Laboratories

In related news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction on Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the acquisition, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.